Patient-specific tumor neoantigen-HLA complex (NeoAg-HLA complex)

The patient-specific HLA class I/II molecule presenting a tumor neoantigen peptide is a molecular complex that serves as the primary signal for T-cell recognition of malignant cells. Human Leukocyte Antigens (HLA) are highly polymorphic proteins that bind peptide fragments and display them on the cell surface for surveillance by T-cell receptors (TCRs). In oncology, somatic mutations in tumor DNA can create 'neoantigens'—novel peptides not present in the normal human proteome. When these neoantigens are processed and presented by the patient's specific HLA alleles, they are recognized as foreign by the immune system, triggering a targeted attack. This complex is the fundamental target for personalized cancer vaccines and adoptive TCR-T cell therapies, which aim to amplify the natural immune response against a patient's unique tumor profile. Because neoantigens are absent from healthy tissues, targeting these complexes offers a high degree of therapeutic specificity, though the approach is limited by the necessity for individualized manufacturing and the risk of tumor immune evasion through the loss of HLA expression.

Other names

Neoepitope-HLA complexTumor-specific antigen-MHC complexPeptide-HLA complexpHLANeoantigen-MHC class I/II complex

Induction of a targeted immune response where T-cell receptors (TCRs) specifically recognize and bind to the neoantigen peptide presented by HLA molecules, leading to the activation of cytotoxic T cells and subsequent lysis of tumor cells.